key: cord-0872596-kapzka8n authors: Dotto, Lara; Kinalski, Mateus de Azevedo; Machado, Pablo Soares; Pereira, Gabriel Kalil Rocha; Sarkis‐Onofre, Rafael; dos Santos, Mateus Bertolini Fernandes title: The mass production of systematic reviews about COVID‐19: An analysis of PROSPERO records date: 2021-02-17 journal: J Evid Based Med DOI: 10.1111/jebm.12426 sha: 5a68ca549b55b63d317850569f317d92b125267a doc_id: 872596 cord_uid: kapzka8n OBJECTIVE: This study aimed to assess the characteristics of different designs of systematic reviews (SRs) registered in the International Prospective Register of Systematic Reviews (PROSPERO) about COVID‐19. METHODS: The search was performed in the PROSPERO database using the strategy proposed by the database and considered only human studies. The last date of the search was April 27, 2020. Full text of all records was accessed, and data were extracted by a single researcher, which was further double‐checked by another researcher. A descriptive analysis was performed considering record characteristics using tables. RESULTS: We included 564 records from which the vast majority were registered as SRs (n = 513, 91%). In general, we found poor reporting and missing or confusing information, since 84% of the records (n = 474) did not report the full search that would be adopted, 16% (n = 90) did not report clearly the databases that would be used, and 49.1% (n = 277) did not report the number of primary outcomes. The main focus of most of the records involved clinical, epidemiological, complication, and laboratory characteristics (n = 173, 30.7%) or the treatment of COVID‐19 (n = 138, 24.5%). CONCLUSION: A large number of SRs about COVID‐19 have been conducted, and many of the assessed records were poorly reported and would be difficult to replicate. Besides, collected data points to an epidemic of redundant reviews on COVID‐19. vaccine is effective in treating COVID-19, 2 though countries that were highly affected by the pandemic tried to redirect different drugs to the treatment of Although there is an urgency in finding an effective answer to manage COVID-19, no definitive response will be found without proper research design, conduct, and report, and there are already some retractions in the literature about studies for the treatment of COVID- 19 . 4 Another example of the importance of well-designed and conducted studies during the pandemic is an earlier study conducted on a small sample of patients that reported a positive effect of the adjunctive use of hydroxychloroquine and azithromycin in critical patients, reducing the convalescence time and fatality rates. 5 However, it turned out that a larger multinational real-world analysis not only did not confirm these previous findings but also observed an increased hazard for a clinically significant occurrence of ventricular arrhythmias and in-hospital death with COVID-19. 3 The adjunctive use of other drugs was also considered and debated (as dexamethasone, favipiravir, ivermectin, remdesivir), but none prove to be efficient, to date. [6] [7] [8] [9] It is well known that systematic reviews with meta-analysis can provide the best levels of evidence, 10 being an important tool to define health care strategies and resource allocation planning. Previous papers 1, 2 have warned about the risk of low quality and duplication of ongoing research that could result in "massive waste in research." 1 Still, in this sense, the Cochrane Handbook for Systematic Reviews of Interventions 11 emphasizes that a systematic review protocol should be developed and registered in specific databases before its start, to avoid reporting bias or the change of the previously planned study design. However, a study by Tricco et al 12 observed that a third of systematic reviews changed or did not specify their primary outcome on the register and that only 18% of published systematic reviews have previously been registered. Considering these aspects, this study aimed to assess the characteristics of different designs of systematic reviews (SR) records registered in the International Prospective Register of Systematic Reviews (PROSPERO) about COVID-19. The study protocol was registered in the open science framework (OSF) and is available at the following link: https://osf.io/9umqj/. We selected SRs or any other knowledge synthesis designs (ie, rapid reviews, umbrella reviews, and living reviews) about COVID- 19 Records identified in PROSPERO were downloaded in Endnote format as control of included studies, and the records' full texts were accessed directly on the PROSPERO platform. Only the first version of each record was considered at this time to standardize the records because it is possible to change information during the study development. We created a standardized form using the Excel software, which was tested by all the researchers to reach a consensus of data collections. Registers were divided among three researchers to perform data extraction, and after, one researcher double-checked all data. In order to register an SR, the PROSPERO database requires different infor- The search yielded 574 records, and 10 were excluded because the full texts were not identified in the PROSPERO platform during the data extraction phase. The majority of these studies were registered as SRs (n = 513, 91%; Table 1 ). The conduct of the majority of the registered records (n = 210, 37.2%; Table 1 ) was not started before April 27, 2020, and only four studies had already performed data extraction/analysis (data extraction n = 1, 0.2%; data analysis n = 3, 0.5%; Table 1 ). The great majority of the records did not report the existence Despite that, 84% of the records (n = 474, Table 1 ) did not report the full search that would be adopted. Also, in 16% of the assessed records, even the databases that would be used were unclear (n = 90, Table 1 ). The number of primary outcomes was unclear in 49.1% of the records (n = 277, Table 1 ). The most proposed synthesis strategy method was meta-analysis (n = 333, 59%; Table 1) , and, as additional analysis, subgroup analysis (n = 386, 68.4%; Table 1 ). The risk of bias tool claimed to be used varied between Cochrane risk of bias tools (n = 147, 26.1%; Chloroquine and/or hydroxychloroquine COVID-19; hence, the mass production of systematic reviews reported in our study could be even bigger. Our assessment was based on the report of the PROSPERO records, and it is possible that certain studies were performed more rigorously than specified in the record. Finally, we assessed only the first version of each PROSPERO record, and it is possible that such records were or will be modified. The assessment of only the first version of the record aimed to standardize the records and to evaluate the first body of the planned methods of these reviews. In the future, it will be possible to monitor changes that were made during the execution of the systematic review. In this sense, although changes in PROSPERO records are acceptable when justified, they may reflect mistakes on planning or lack of expertise on the analysis. It has been greatly defended that the protocol elaboration is a crucial step in the systematic review process. Thus it should be carefully and adequately planned, registered, and made freely accessible to the scientific community as a reflection of good research practice. 18, 19 Also, it is important to highlight that guidelines such as PRISMA-P are available and are strongly recommended to enable quality reports of systematic review protocols creation. 20 In conclusion, a massive number of SRs about COVID-19 have been conducted, whose PROSPERO records present varied characteristics. Furthermore, many of the assessed records were poorly reported and would be difficult, if not impossible, to replicate, but these results should be interpreted with caution. Even considering that pandemic periods demand urgency in evidence compilation, it is mandatory to conduct research with good practices, focusing on quality reporting, adopting the necessary methods to access the knowledge on the theme, and attempting to establish collaborations among research groups rather than duplicate SR studies. Waste in COVID-19 research COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance A review of the safety of favipiravira potential treatment in the COVID-19 pandemic? Available evidence and ongoing clinical trials of remdesivir: could it be a promising therapeutic option for COVID-19? Front Pharmacol Dexamethasone for COVID-19? Not so fast Fundamentals of Clinical Trials Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration A third of systematic reviews changed or did not specify the primary outcome: a PROSPERO register study One more time': why replicating some syntheses of evidence relevant to COVID-19 makes sense Discrepancies in meta-analyses answering the same clinical question were hard to explain: a meta-epidemiological study Lessons from COVID-19 to future evidence synthesis efforts: first living search strategy and out of date scientific publishing and indexing industry (submitted) Methodological challenges in studying the COVID-19 pandemic crisis When and how to replicate systematic reviews The nuts and bolts of PROSPERO: an international prospective register of systematic reviews How to reduce unnecessary duplication: use PROSPERO Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement The mass production of systematic reviews about COVID-19: An analysis of PROSPERO records The authors declare no conflict of interest. Rafael Sarkis-Onofre https://orcid.org/0000-0002-1514-7879